Steroid-Sparing Effect With Pimecrolimus in Pediatric Patients With Atopic Dermatitis

• Status: Completed
• Trial end date: 2004-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will investigate the steroid sparing effect of pimecrolimus cream 1% in pediatric atopic dermatitis

• Phase: Phase 3

Details

• Lead Sponsor: Novartis
• Treatments: Pimecrolimus; Tacrolimus

Criteria

Inclusion Criteria:

• Outpatients aged 2 to < 18 years with severe AD (score 8 or 9 according to Rajka and Langeland)

• responded to 21 days of treatment with prednicarbate cream 0.25% during screening phase

Exclusion Criteria:

• Patients who had received phototherapy, systemic or topical therapy or systemic corticosteroids shortly prior to study